Information for consumers
SOLIRIS is used to treat patients with PNH to reduce hemolysis (destruction of red blood cells) or to treat patients with chronic atypical HUS, a very rare disease that affects the blood system, kidney and sometimes other body organs.
SOLIRIS works by decreasing the destruction of patients’ red blood cells and platelets, but it also lowers the ability of their immune system to fight infections, particularly meningococcal disease caused by
Neisseria meningitidis. Patients must be vaccinated with a meningococcal vaccine prior to, or at the time of, initiating SOLIRIS, unless otherwise recommended by their healthcare professional. Meningococcal vaccine prevents meningococcal infection, (an inflammation of the membranes that cover the brain and spinal cord). Patients may also be revaccinated according to current medical guidelines for vaccine use.
Patients who receive SOLIRIS must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary. Patients, who receive SOLIRIS will be provided a card to carry with them, listing specific trigger symptoms of infection. This card is named: “
Patient Safety Card”. Patients should carry this card with them at all times during treatment and for 3 months after their last dose of SOLIRIS. Patients need to show their Patient Safety Card to any healthcare professional they see during this time.
Patients should immediately inform their doctor if they notice any symptoms listed on their “
Patient Safety Card”, such as: headache with nausea or vomiting; headache and a fever; headache with a stiff neck or stiff back; fever; fever and a rash; confusion; muscle aches with flu-like symptoms; or eyes sensitive to light.
Patients and caregivers should contact their healthcare professional for more information about vaccination before starting treatment with SOLIRIS or if they are already being treated with SOLIRIS.
Information for healthcare professionals
It is recommended that careful consideration be given to the timing of meningococcal vaccination relative to the administration of SOLIRIS in patients who initiate therapy and also for those receiving maintenance therapy.
-
For patients stabilized on SOLIRIS and receiving maintenance therapy, and for whom additional vaccination is warranted, vaccination is only recommended when the underlying complement-mediated disease is clinically controlled with SOLIRIS, and within one week following SOLIRIS infusion, when systemic SOLIRIS concentrations are considered to be relatively high.
-
All patients taking SOLIRIS must be vaccinated with a meningococcal vaccine prior to, or at the time of, initiating SOLIRIS.
-
Patients who start on SOLIRIS treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics for 2 weeks after they are vaccinated.
Healthcare professionals are reminded to provide their patients with information from the recently updated
Patient Information Brochure to increase their awareness of potential serious infections and their signs and symptoms. All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.
Action taken by Health Canada
Health Canada in collaboration with Alexion has updated the
SOLIRIS Canadian Product Monograph. In order to help Canadians to make informed decisions about their medication choices, Health Canada has also shared this important safety information by publishing a
summary of the safety review on its Web site.
Health Canada is communicating this important safety information to healthcare professionals and to the public through its
Healthy Canadians Web site.